Nausea Clinical Trial
Official title:
Is Intra-operative Acupuncture Point P6 Stimulation as Effective as Traditional Pharmacotherapy in Reducing Nausea and Vomiting During Cesarean Section With Regional Anesthesia?
The purpose of this study is to compare the effectiveness of acupressure point P6 stimulation versus intravenous ondansetron plus metoclopramide versus no antiemetic prophylaxis during elective cesarean section under regional anesthesia.
The design of the study consists of the randomization of subjects undergoing cesarean section
with regional anesthesia in one of three groups. The study is not blinded; as the
participants will know which method they are being treated with because of the difference in
site and nature of the acupuncture point P6 stimulation. The randomization of patients will
be done by a computer to avoid bias before the informed consent form (ICF) is signed by the
patients. The computer will generate three sets of random numbers for the three groups. Once
the consent form is signed, the investigator will allocate the patients serially to the
groups having those numbers . The randomization will be created before the study begins and
will assign 180 subjects into one of the three groups to receive the treatment as follows:
Group I (n=60): Will be the control group patients and will not be given traditional medical
therapy nor will receive acupuncture point P6 stimulation prior to administration of the
standardized epidural anesthesia, as outlined below.
Group II (n=60): Will receive traditional medical management, consisting of 10 mg
metoclopramide IV and 8 mg of ondansetron IV immediately prior to administration of the
standardized regional anesthesia, as outlined below.
Group III (n=60): Will receive acupuncture point P6 stimulation. This is a stimulation of the
chi channel at the master of the heart (MH8 position) at the small depression of the volar
surface of the distal right forearm just above the crest of the wrist. The device will be put
on the patients in the operating room prior to administration of the regional anesthesia and
will be removed after the cesarean section is complete. The device will be removed from the
patient in the operating room, before the patient is transported to the recovery room.
Patients will receive continuous stimulation at a level that is comfortable for the patient
prior to administration of the standardized regional anesthesia, as outlined below.
After the subjects have been randomly assigned to one of the three groups, subjects will
receive the standardized regional anesthesia consisting of 2 milliliters (10 milligrams) of
0.5% bupivicaine and 20 micrograms of fentanyl and 100 micrograms of epinephrine. Patients
will offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no
nausea, 10 = worst nausea every experienced).
An Apfel score, which is used to predict the risk of experiencing post-operative nausea and
vomiting (PONV), will also be determined with each subject.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01649258 -
Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy
|
Phase 1 | |
Completed |
NCT02939287 -
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
|
Phase 3 | |
Not yet recruiting |
NCT06464926 -
Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)
|
N/A | |
Not yet recruiting |
NCT06055192 -
Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022
|
||
Recruiting |
NCT04091789 -
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
|
Phase 2 | |
Completed |
NCT02462811 -
A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)
|
Phase 3 | |
Completed |
NCT01007500 -
Effect of Dexamethasone Combined With Ondansetron on Postoperative Nausea and Vomiting in Patients With Patient-controlled Analgesia After Video-assisted Thoracoscopic Surgery
|
Phase 4 | |
Recruiting |
NCT00528554 -
Laser Acupuncture Against Nausea in Children
|
N/A | |
Completed |
NCT00537875 -
Evaluation of the Effect of Zingiber Officinalis on Nausea and Vomiting in Patients Receiving Cisplatin Based Regimens
|
N/A | |
Completed |
NCT00394966 -
A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED)
|
Phase 2 | |
Completed |
NCT00946387 -
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT00947128 -
To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions
|
Phase 1 | |
Recruiting |
NCT05433636 -
Mindful Waiting Room
|
N/A | |
Not yet recruiting |
NCT04827108 -
Psychometric Properties of the Chinese Version of PeNAT
|
||
Not yet recruiting |
NCT04853303 -
VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK
|
N/A | |
Terminated |
NCT04247100 -
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
|
N/A | |
Recruiting |
NCT04181346 -
Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting
|
Phase 2 | |
Recruiting |
NCT03679182 -
Efficacy and Safety of Olanzapine for the Treatment of Nausea and Vomiting in Palliative Cancer Care
|
Phase 2 | |
Completed |
NCT02618343 -
EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron
|
N/A | |
Terminated |
NCT01405924 -
Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)
|
Phase 2 |